Introduction Acute lower limb ischemia results from thrombosis or embolization of diseased native artery or previously implanted bypass graft. When this occurs, several options are available to restore blood flow: catheter-directed thrombolysis, mechanical thrombectomy or open surgery. Fundamental reasons to apply percutaneous interventions are avoiding open procedures in high risk patients, and avoiding difficult dissection through scar tissue. Case Outline A 67-year-old male was admitted at our Institution for critical limb ischemia. After performed angiography the diagnosis of occluded femoropopliteal graft was established. Occlusion was resolved by catheter-directed thrombolysis with plasmin. Culprit lesions were treated by angioplasty. Conclusion Our patient underwent a successful thrombolysis of occluded femoropopliteal graft with locally-delivered human plasmin.
INTRODUCTION
Peripheral artery occlusive disease is common and potentially serious problem. It is usually caused by atherosclerotic plaques which cause reduction of blood flow in lower extremities. It affects approximately 20% of adults older than 55 years, and increases significantly with age rising to 25%, among those over 80 years of age [1, 2] .
Acute lower limb ischemia results from thrombosis or embolization of diseased native artery or previously implanted bypass graft. When such event occurs several options are available to restore blood flow: catheter-directed thrombolysis, mechanical thrombectomy or open surgery which is associated with higher morbidity and mortality compared with the first two methods of revascularization [3, 4] .
Fundamental reasons to apply percutaneous interventions thus are avoiding open surgical procedures in high risk patients, and avoiding difficult dissection through scar tissue.
CASE REPORT
A 67-year-old male was admitted to our hospital due to critical limb ischemia. The patient was experiencing rest pain in the right foot with a sudden onset three days earlier. Past medical history included hypertension, dyslipidemia and heavy smoking. Three years prior to this hospitalization the patient underwent transluminal angioplasty and stenting of left iliac artery and redo right femoropopliteal above knee bypass with a Dacron graft. Clinical examination revealed absent pulses distal from the right groin. Ankle-brachial index on admission on the right leg was 0. CT angiography ( Figure 1 ) and color duplex scan confirmed occlusion of femoropopliteal bypass, and significant stenosis of right iliac artery. The popliteal artery was patent as were all three crural vessels.
After preparation, the patient was transferred to the Radiology Department. After puncturing contralateral common femoral artery, a guidewire was inserted and a six French sheet was placed. Heparin (10000 IU) was given intravenously. The stenotic right iliac artery was resolved by balloon angioplasty. A guidewire was advanced into the occluded femoropopliteal graft. A multi-side-hole infusion catheter ( Angiodynamics Unifuse catheter, USA) was positioned into the thrombosed graft. Plasmin (Talecris Biotherapeutics, USA) infusion was started initially with pulse spray (1 ml per min, for 30 ml), for the initiation of thrombolysis, and continued for four and half hours of 45 ml of solution. Total dose of 150 mg (75 ml) of plasmin was administered. Followup angiography was performed after 2 hours and at the end of the treatment after 5 hours. Final angiography (Figure 2 ) revealed resolution of all intraluminal filling defects, and critical stenosis at the level of proximal and distal anastomosis of femoropopliteal bypass.
Former was resolved with stenting and latter by balloon angioplasty. There was no evidence of distal embolization. Double antiplatelet therapy, with aspirin and clopidogrel, was continued after intervention.
Seven days later the patient was discharged with a patent graft and ankle-brachial index 1.0. One year followup showed full patency of femoropopliteal graft on CT angiography with patient leading normal life ( Figure 3 ).
DISCUSSION
In past, several clinical studies have been conducted comparing the effects of locally delivered plasminogen activators (PA) with open surgery in the treatment of acute lower limb ischemia [5] [6] [7] [8] .
The Rochester trial [5] compared catheter-directed urokinase infusion with surgery for acute limb ischemia. During one year follow-up no difference was found in limb salvage between groups and mortality was significantly reduced with the urokinase group of patients. Bleeding complications were increased in the urokinase group compared to surgery.
The STILE trial (Surgery versus Thrombolysis for Ischemia of the Lower Extremity) [6] randomized patients to surgery or catheter-directed thrombolysis with urokinase or recombinant tissue plasminogen activator, but it differed in that patients had acute (<14) and chronic (>14) limb ischemia. Intracranial hemorrhage occurred in 1.6% of patients, which is similar to the rate recorded in the TOPAS trial. A large benefit (fewer amputations, increase in amputation-free survival) was achieved for our patients with acute ischemia who were randomized to thrombolysis. However, the patients with chronic ischemia who were randomized to surgery experienced fewer amputations and improved amputation-free survival. These results were maintained at 1-year follow-up.
The TOPAS (Thrombolysis or Peripheral Arterial Surgery) [7, 8] trial randomized patients to recombinant urokinase or surgery, but found no difference in amputation rate (15% vs. 13%) or in amputation-free survival at six months and one year respectively (20% vs. 17%). Bleeding complications, however, were significantly increased in patients randomized to urokinase therapy.
Results from randomized clinical trials suggest that thrombolytic therapy is superior to surgery for treatment of acute (less than 14 days) occlusions regarding bypass graft occlusions and long occlusions without adequate run-off vessel suitable for surgical bypass. However, open surgery should be recommended for subacute or chronic occlusions and in native arteries occlusions [9] .
Currently held opinions on the role of catheter-based thrombolysis therapy in the patients with acute leg ischemia, can be considered as complementary with surgical or percutaneous revascularization with an acceptably low complication rate [10, 11] .
The goal of catheter-directed intra-arterial thrombolysis is to eliminate occluding thrombus and restore native artery or bypass graft patency. In that way the underlying lesion is revealed and could be treated by angioplasty thus avoiding open surgery and reducing morbidity and mortality [12] .
It has been shown that systemic infusion of plasminogen activators is ineffective when compared to catheter-directed intra-thrombus infusion [13, 14] . Catheter-directed thrombolysis provides maximal delivery of agent to a thrombus, thus improving the degree of thrombolysis [15, 16] .
The fibrinolytic system is based upon conversion of an inactive pro-enzyme plasminogen, to active form plasmin by plasmin activators. Physiologic dissolution of thrombus occurs by plasmin action on fibrin [17] . Free plasmin is inactivated rapidly by plasma alpha-2-antiplasmin, a naturally occurring protease inhibitor. This results in both a decrease in plasmin production and a decrease in the dissolution of fibrin clots [18] . But when bound to a thrombus, plasmin is protected from inhibition [19] , thereby allowing an effective thrombolysis.
The limitations of plasminogen activators (PA) usage is that they are released systemically even when delivered locally by catheter. This increases a bleeding risk because fibrinolysis is activated at sites of remote vascular injury or malformation [20] . The most severe hemorrhagic complication of catheter-delivered PA is intracranial hemorrhage, occurring in 1-2.8% of patients [21, 22, 23] and higher, correlated with poor hypertensive control [24] .
Different studies have suggested that the use of urokinase may be associated with a lower incidence of hemorrhagic complications compared to recombinant tissue plasminogen activator (rtPA) [9] .
However, in 2010 Cochrane systematic review stated that the incidence of bleeding complications was not statistically significantly greater with rtPA than with other regimes [20] .
The other drawback of PA use is that they need plasminogen in order to express action. Since thrombus-associated plasminogen may be present in limited supply [25] , it can result in suboptimal lysis of retracted thrombi and incomplete reperfusion of occluded vessels.
On the contrary, human plasmin biochemisty is favorable because it is rapidly and irreversibly inhibited by alpha-2-antiplasmin and it is a direct-acting fibrinolytic [25, 26] not requiring plasminogen to achieve fibrinolysis. The physiologic relevance of these attributes of plasmin is supported by animal studies [26] . Experimental data indicate that we should recognize plasmin as viable, even preferable thrombolytic agent. The most recent pre-clinical studies and reports confirm that plasmin has marked hemostatic safety advantage over t-PA, and superior-thrombolytic efficiency, when delivered by catheter to occluded arteries [27] [28] [29] [30] [31] .
After more than 50 years, the field has come full circle, and plasmin as the thrombolytic agent and catheter use for local delivery of agent may represent a step forward in thrombolytic therapy compared to PA [32] .
Marder [33] proposed that locally-delivered plasmin could also have a significant role in the treatment of deep vein thrombosis due to its safety and efficacy compared to PA.
First-in-human experiences with locally administered plasmin were gained by Shlansky-Goldberg et al. [27, 34] in the study where thrombosed synthetic hemodialysis access grafts were treated for occlusion. The overall conclusion of this Phase I study was that human plasmin was safe and well tolerated in the hemodialysis graft occlusion subject population, and showed a dose response thrombolytic trend.
Our patient was a part of Phase I PRIORITY (Plasmin Revascularization for the Ischemic Lower Extremity) study -the first human dose-escalation trial of plasmin in patients with acute limb ischemia. Although successful in our case, we should wait end of the study to obtain more valid conclusions.
КРАТАК САДРЖАЈ Увод
Ис хе ми ја до њих екс тре ми те та је по сле ди ца тром бо зе или ем бо ли за ци је обо ле ле на тив не ар те ри је или им план ти-ра ног граф та. По сто ји не ко ли ко на чи на ле че ња ис хе ми је: тром бо ли за ка те те ром, ме ха нич ка тром бек то ми ја и хи рур-шко ле че ње. Основ ни раз ло зи за при ме ну пер ку та них ин-тер вен ци ја је сте из бе га ва ње кла сич ног хи рур шког ле че ња код бо ле сни ка с ви со ким ри зи ком, као и из бе га ва ње пре-па ри са ња крв ног су да у ожиљ ку. При каз бо ле сни ка Му шка рац стар 67 го ди на при мљен је у бол ни цу због кри тич не ис хе ми је до њих екс тре ми те та. По учи ње ној ан ги о гра фи ји ди јаг но сти ко ва на је тром бо за фе мо-ро по пли те ал ног граф та. Оклу зи ја је ре ше на при ме ном пла-зми на уз упо тре бу ин тра ар те риј ског ка те те ра. Сте но зе ко је су от кри ве не по сле тром бо ли зе ле че не су ан ги о пла сти ком. За кљу чак Тром бо ли зом уз при ме ну пла зми на и ин тра ар-те риј ског ка те те ра успе шно је из ле че на оклу зи ја фе мо ро-по пли те ал ног граф та. Кључ не ре чи: пер ку та не ин тер вен ци је; тром бо ли за ка те те-ром; ху ма ни пла змин; фе мо ро по пли те ал ни графт 
